APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin Inhibitors for the Treatment of Refractory Gout

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Interleukin Inhibitors for the Treatment of Refractory Gout Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025184 pages

Choose your research edition.

Industry ResearchInterleukin Inhibitors for the Treatment of Refractory Gout Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin Inhibitors for the Treatment of Refractory Gout Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Interleukin Inhibitors for the Treatment of Refractory Gout Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin Inhibitors for the Treatment of Refractory Gout Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin Inhibitors for the Treatment of Refractory Gout Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Interleukin Inhibitors for the Treatment of Refractory Gout market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Interleukin Inhibitors for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Interleukin Inhibitors for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin Inhibitors for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Interleukin Inhibitors for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Interleukin Inhibitors for the Treatment of Refractory Gout include Biogen, Fresenius Kabi, Hetero, Novartis, Roche, Sobi, Bio-Thera Solutions, Hangzhou Bozhirui Biopharmaceutical and Zhuhai Livzon Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Interleukin Inhibitors for the Treatment of Refractory Gout market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Interleukin Inhibitors for the Treatment of Refractory Gout and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Interleukin Inhibitors for the Treatment of Refractory Gout sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Interleukin Inhibitors for the Treatment of Refractory Gout market size, projected growth trends, production technologies, key applications, and end-use industries.

Interleukin Inhibitors for the Treatment of Refractory Gout Segment by Company

Biogen

Fresenius Kabi

Hetero

Novartis

Roche

Sobi

Bio-Thera Solutions

Hangzhou Bozhirui Biopharmaceutical

Zhuhai Livzon Biotechnology

Interleukin Inhibitors for the Treatment of Refractory Gout Segment by Type

Tocilizumab

Canakinumab

Anakinra

Interleukin Inhibitors for the Treatment of Refractory Gout Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Interleukin Inhibitors for the Treatment of Refractory Gout Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin Inhibitors for the Treatment of Refractory Gout market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin Inhibitors for the Treatment of Refractory Gout and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin Inhibitors for the Treatment of Refractory Gout.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin Inhibitors for the Treatment of Refractory Gout market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Interleukin Inhibitors for the Treatment of Refractory Gout manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Interleukin Inhibitors for the Treatment of Refractory Gout in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Interleukin Inhibitors for the Treatment of Refractory Gout in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Interleukin Inhibitors for the Treatment of Refractory Gout Industry Trends Table 2. Interleukin Inhibitors for the Treatment of Refractory Gout Industry Drivers Table 3. Interleukin Inhibitors for the Treatment of Refractory Gout Industry Opportunities and Challenges Table 4. Interleukin Inhibitors for the Treatment of Refractory Gout Industry Restraints Table 5. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Manufacturers Table 9. Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Interleukin Inhibitors for the Treatment of Refractory Gout Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Interleukin Inhibitors for the Treatment of Refractory Gout Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Interleukin Inhibitors for the Treatment of Refractory Gout Manufacturers, Product Type & Application Table 13. Global Interleukin Inhibitors for the Treatment of Refractory Gout Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Interleukin Inhibitors for the Treatment of Refractory Gout by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tocilizumab Table 17. Major Manufacturers of Canakinumab Table 18. Major Manufacturers of Anakinra Table 19. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2021-2026) & (K Units) Table 21. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2027-2032) & (K Units) Table 22. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Type (2021-2026) Table 23. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Type (2027-2032) Table 24. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2021-2026) & (K Units) Table 26. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2027-2032) & (K Units) Table 27. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2026) Table 28. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital and Clinic Table 30. Major Manufacturers of Retail Pharmacies Table 31. Major Manufacturers of Other Table 32. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2021-2026) & (K Units) Table 34. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2027-2032) & (K Units) Table 35. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Application (2021-2026) Table 36. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Application (2027-2032) Table 37. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2021-2026) & (K Units) Table 39. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2027-2032) & (K Units) Table 40. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2026) Table 41. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Application (2027-2032) Table 42. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2021-2026) & (K Units) Table 44. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Region (2021-2026) Table 45. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 49. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 50. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 52. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 59. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2026) Table 63. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Region (2027-2032) Table 64. Biogen Company Information Table 65. Biogen Business Overview Table 66. Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 68. Biogen Recent Development Table 69. Fresenius Kabi Company Information Table 70. Fresenius Kabi Business Overview Table 71. Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 73. Fresenius Kabi Recent Development Table 74. Hetero Company Information Table 75. Hetero Business Overview Table 76. Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 78. Hetero Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 83. Novartis Recent Development Table 84. Roche Company Information Table 85. Roche Business Overview Table 86. Roche Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Roche Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 88. Roche Recent Development Table 89. Sobi Company Information Table 90. Sobi Business Overview Table 91. Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 93. Sobi Recent Development Table 94. Bio-Thera Solutions Company Information Table 95. Bio-Thera Solutions Business Overview Table 96. Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 98. Bio-Thera Solutions Recent Development Table 99. Hangzhou Bozhirui Biopharmaceutical Company Information Table 100. Hangzhou Bozhirui Biopharmaceutical Business Overview Table 101. Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 103. Hangzhou Bozhirui Biopharmaceutical Recent Development Table 104. Zhuhai Livzon Biotechnology Company Information Table 105. Zhuhai Livzon Biotechnology Business Overview Table 106. Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio Table 108. Zhuhai Livzon Biotechnology Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Interleukin Inhibitors for the Treatment of Refractory Gout Distributors List Table 112. Interleukin Inhibitors for the Treatment of Refractory Gout Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Interleukin Inhibitors for the Treatment of Refractory Gout Product Image Figure 2. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size (2021-2032) & (US$ Million) Figure 4. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales (2021-2032) & (K Units) Figure 5. Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Interleukin Inhibitors for the Treatment of Refractory Gout Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tocilizumab Image Figure 9. Canakinumab Image Figure 10. Anakinra Image Figure 11. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032) Figure 14. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Retail Pharmacies Image Figure 19. Other Image Figure 20. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032) Figure 23. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032) Figure 26. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 28. U.S. Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 33. Germany Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 40. China Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Country (2021-2032) Figure 48. Brazil Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Interleukin Inhibitors for the Treatment of Refractory Gout Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 59. North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 61. Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Interleukin Inhibitors for the Treatment of Refractory Gout Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Interleukin Inhibitors for the Treatment of Refractory Gout Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Tocilizumab
  • Canakinumab
  • Anakinra
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Biogen
  • Fresenius Kabi
  • Hetero
  • Novartis
  • Roche
  • Sobi
  • Bio-Thera Solutions
  • Hangzhou Bozhirui Biopharmaceutical
  • Zhuhai Livzon Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Dynamics
  1. 2.1 Interleukin Inhibitors for the Treatment of Refractory Gout Industry Trends
  2. 2.2 Interleukin Inhibitors for the Treatment of Refractory Gout Industry Drivers
  3. 2.3 Interleukin Inhibitors for the Treatment of Refractory Gout Industry Opportunities and Challenges
  4. 2.4 Interleukin Inhibitors for the Treatment of Refractory Gout Industry Restraints
3 Interleukin Inhibitors for the Treatment of Refractory Gout Market by Manufacturers
  1. 3.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Manufacturers (2021-2026)
  3. 3.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Interleukin Inhibitors for the Treatment of Refractory Gout Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Interleukin Inhibitors for the Treatment of Refractory Gout Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Interleukin Inhibitors for the Treatment of Refractory Gout Manufacturers, Product Type & Application
  7. 3.7 Global Interleukin Inhibitors for the Treatment of Refractory Gout Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Interleukin Inhibitors for the Treatment of Refractory Gout Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Interleukin Inhibitors for the Treatment of Refractory Gout Tier 1, Tier 2, and Tier 3
4 Interleukin Inhibitors for the Treatment of Refractory Gout Market by Type
  1. 4.1 Interleukin Inhibitors for the Treatment of Refractory Gout Type Introduction
  2. 4.1.1 Tocilizumab
  3. 4.1.2 Canakinumab
  4. 4.1.3 Anakinra
  5. 4.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type
  6. 4.2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Type (2021-2032)
  8. 4.2.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Type (2021-2032)
  9. 4.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type
  10. 4.3.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Type (2021-2032)
  12. 4.3.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Type (2021-2032)
5 Interleukin Inhibitors for the Treatment of Refractory Gout Market by Application
  1. 5.1 Interleukin Inhibitors for the Treatment of Refractory Gout Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application
  6. 5.2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Application (2021-2032)
  8. 5.2.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Market Share by Application (2021-2032)
  9. 5.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application
  10. 5.3.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Application (2021-2032)
  12. 5.3.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Application (2021-2032)
6 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region
  1. 6.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2021-2032)
  3. 6.2.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Region (2021-2026)
  4. 6.2.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region
  1. 7.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region
  2. 7.1.1 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2021-2026)
  4. 7.1.3 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue by Region (2027-2032)
  5. 7.1.4 Global Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032)
  8. 7.2.2 North America Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032)
  11. 7.3.2 Europe Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Interleukin Inhibitors for the Treatment of Refractory Gout Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Fresenius Kabi
  8. 8.2.1 Fresenius Kabi Company Information
  9. 8.2.2 Fresenius Kabi Business Overview
  10. 8.2.3 Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Fresenius Kabi Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  12. 8.2.5 Fresenius Kabi Recent Developments
  13. 8.3 Hetero
  14. 8.3.1 Hetero Company Information
  15. 8.3.2 Hetero Business Overview
  16. 8.3.3 Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hetero Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  18. 8.3.5 Hetero Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Sobi
  32. 8.6.1 Sobi Company Information
  33. 8.6.2 Sobi Business Overview
  34. 8.6.3 Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sobi Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  36. 8.6.5 Sobi Recent Developments
  37. 8.7 Bio-Thera Solutions
  38. 8.7.1 Bio-Thera Solutions Company Information
  39. 8.7.2 Bio-Thera Solutions Business Overview
  40. 8.7.3 Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Thera Solutions Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  42. 8.7.5 Bio-Thera Solutions Recent Developments
  43. 8.8 Hangzhou Bozhirui Biopharmaceutical
  44. 8.8.1 Hangzhou Bozhirui Biopharmaceutical Company Information
  45. 8.8.2 Hangzhou Bozhirui Biopharmaceutical Business Overview
  46. 8.8.3 Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hangzhou Bozhirui Biopharmaceutical Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  48. 8.8.5 Hangzhou Bozhirui Biopharmaceutical Recent Developments
  49. 8.9 Zhuhai Livzon Biotechnology
  50. 8.9.1 Zhuhai Livzon Biotechnology Company Information
  51. 8.9.2 Zhuhai Livzon Biotechnology Business Overview
  52. 8.9.3 Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Zhuhai Livzon Biotechnology Interleukin Inhibitors for the Treatment of Refractory Gout Product Portfolio
  54. 8.9.5 Zhuhai Livzon Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Interleukin Inhibitors for the Treatment of Refractory Gout Value Chain Analysis
  2. 9.1.1 Interleukin Inhibitors for the Treatment of Refractory Gout Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Interleukin Inhibitors for the Treatment of Refractory Gout Production Mode & Process
  6. 9.2 Interleukin Inhibitors for the Treatment of Refractory Gout Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Interleukin Inhibitors for the Treatment of Refractory Gout Distributors
  9. 9.2.3 Interleukin Inhibitors for the Treatment of Refractory Gout Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst